These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. Matralis AN; Katselou MG; Nikitakis A; Kourounakis AP J Med Chem; 2011 Aug; 54(15):5583-91. PubMed ID: 21702499 [TBL] [Abstract][Full Text] [Related]
11. Syntheses and biological evaluation of novel quinuclidine derivatives as squalene synthase inhibitors. Ishihara T; Kakuta H; Moritani H; Ugawa T; Sakamoto S; Tsukamoto S; Yanagisawa I Bioorg Med Chem; 2003 May; 11(11):2403-14. PubMed ID: 12735986 [TBL] [Abstract][Full Text] [Related]
12. The hypolipidemic activity of novel benzofuran-2-carboxamide derivatives in Triton WR-1339-induced hyperlipidemic rats: a comparison with bezafibrate. Shattat G; Al-Qirim T; Sweidan K; Shahwan M; El-Huneidi W; Al-Hiari Y J Enzyme Inhib Med Chem; 2010 Dec; 25(6):751-5. PubMed ID: 20590406 [TBL] [Abstract][Full Text] [Related]
13. Design of novel potent antihyperlipidemic agents with antioxidant/anti-inflammatory properties: exploiting phenothiazine's strong antioxidant activity. Matralis AN; Kourounakis AP J Med Chem; 2014 Mar; 57(6):2568-81. PubMed ID: 24568631 [TBL] [Abstract][Full Text] [Related]
14. Antihyperlipidemic morpholine derivatives with antioxidant activity: An investigation of the aromatic substitution. Ladopoulou EM; Matralis AN; Nikitakis A; Kourounakis AP Bioorg Med Chem; 2015 Nov; 23(21):7015-23. PubMed ID: 26433631 [TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization in vitro of EP2306 and EP2302, potent inhibitors of squalene synthase and lipid biosynthesis. Tavridou A; Kaklamanis L; Megaritis G; Kourounakis AP; Papalois A; Roukounas D; Rekka EA; Kourounakis PN; Charalambous A; Manolopoulos VG Eur J Pharmacol; 2006 Mar; 535(1-3):34-42. PubMed ID: 16545796 [TBL] [Abstract][Full Text] [Related]
16. Anti-inflammatory and Hypolipidemic Effect of Novel Conjugates with Trolox and Other Antioxidant Acids. Theodosis-Nobelos P; Kourounakis PN; Rekka EA Med Chem; 2017; 13(3):214-225. PubMed ID: 27823562 [TBL] [Abstract][Full Text] [Related]
17. Squalene synthase inhibitors reduce plasma triglyceride through a low-density lipoprotein receptor-independent mechanism. Hiyoshi H; Yanagimachi M; Ito M; Saeki T; Yoshida I; Okada T; Ikuta H; Shinmyo D; Tanaka K; Kurusu N; Tanaka H Eur J Pharmacol; 2001 Nov; 431(3):345-52. PubMed ID: 11730728 [TBL] [Abstract][Full Text] [Related]
18. Discovery of novel tricyclic compounds as squalene synthase inhibitors. Ichikawa M; Ohtsuka M; Ohki H; Haginoya N; Itoh M; Sugita K; Usui H; Suzuki M; Terayama K; Kanda A Bioorg Med Chem; 2012 May; 20(9):3072-93. PubMed ID: 22464687 [TBL] [Abstract][Full Text] [Related]
19. Relationships between lipophilicity and biological activities in a series of indoline-based anti-oxidative acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors. Takahashi K; Kunishiro K; Kasai M; Miike T; Kurahashi K; Shirahase H Arzneimittelforschung; 2008; 58(12):666-72. PubMed ID: 19202739 [TBL] [Abstract][Full Text] [Related]